To determine the superiority of chondrogenic potential from BMSCs using an ultra-purified alginate gel over a commercial grade one and to assess the reparative tissues treated with BMSCs and a purified alginate in rabbit cartilage defect model. Methods: Ultra-purified alginate (Sea Matrix ® , Mochida Pharma., Japan, endotoxin level of 5.76 EU/g) and commercial grade one (Sodium Alginate 500, Wako, Japan, endotoxin level of 75,950 EU/g) were prepared. Cytotoxicity of CaCl 2 : BMSCs in alginate were exposed to 50, 100, 200, and 400 mM CaCl 2 . The living cells were counted with Cell Counting Kit-8 (CCK-8). Proliferation assay: BMSCs encapsulated in purified and commercial grade alginate beads were cultured in DMEM with 10% FBS. At 0, 1, 2, 3, and 7 days, the viable cells were counted with CCK-8. Alginate beads culture: Alginate beads containing BMSCs were cultured in chondrogenic medium containing TGF-b3. At 7 and 14 days, relative gene expressions were analyzed by real-time RT-PCR. At 14 and 21 days, each alginate bead was histologically evaluated. Rabbit model:
Purpose: Articular cartilage shows poor intrinsic repair, leading to progressive joint damage. Therapies like marrow stimulation or tissue engineering of cartilage depend on the chondrogenic differentiation of progenitor cells. However, this chondrogenic differentiation needs to take place in a diseased joint with an altered environment. We postulate that catabolic factors in this environment will inhibit chondrogenesis of progenitor cells. Methods: We examined the effect of interleukin-1 (Il-1) and tumour necrosis factor alpha (TNFalpha) on human mesenchymal stem cells undergoing chondrogenic differentiation. In addition, osteoarthritis synovium derived conditioned medium was added to human mesenchymal stem cells undergoing chondrogenic differentiation. Chondrogenesis was examined by determining the mRNA levels of the chondrogenic markers collagen type II and aggrecan. Additionally, the hypertrophy marker collagen type X was examined. Proteoglycan deposition was analyzed by safranin O staining of histological sections. Results: Chondrogenesis of human mesenchymal stem cells, as determined by safranin O proteoglycan staining, was completely abolished at day 14 by adding Il-1 (10 ng/mL) from day 0, 3, 7 and 10 onwards. Under these conditions the expression of type II collagen and aggrecan mRNA as well as the hypertrophy marker collagen type X were also blocked completely, except by late addition of Il-1 (day 10), resulting in only a partial inhibition of these mRNA markers. Il-1 appears to be a very potent inhibitor of chondrogenesis, not only at the onset, but throughout the process of chondrogenesis Il-1 as well as TNF-alpha inhibited chondrogenesis in a dose-dependent manner. Even at the lowest dose tested (0.1 ng/mL) Il-1 and TNFalpha downregulated the mRNA levels of collagen II, aggrecan and collagen type X. However, TNFalpha showed less potent effects on this downregulation than Il-1. Moreover, TNFalpha did not inhibit safranin O staining completely even at the highest concentration applied (10 ng/mL). In contrast, safranin O staining was already fully blocked by 1.0 ng/mL Il-1, indicating the greater potency of Il-1 in inhibiting chondrogenesis. Addition of osteoarthritic conditioned medium, containing an unknown mixture of anabolic and catabolic factors, strongly inhibited chondrogenesis of differentiating mesenchymal stem cells. Conditioned medium of synovia of five different patients inhibited proteoglycan deposition. In addition, chondrogenic mRNA markers were inhibited strongly in all patients but one, in which they were slightly stimulated. These results show that chondrogenesis of differentiating mesenchymal stem cells is inhibited by factors produced by OA synovium. Conclusions: Our study shows for the first time that chondrogenesis of human mesenchymal stem cells is blocked by single catabolic factors as well as factors produced by osteoarthritic synovium. Our findings have major implications for therapies that are currently being applied or developed. Therapies such as tissue engineering or marrow stimulation techniques depend on tissue repair and chondrogenesis by mesenchymal stem cells. In addition, the intrinsic repair response will be blocked by catabolic factors present in disease joints. Successful cartilage regeneration can be expected to fail if the catabolic environment of a damaged joint is not altered. Our study shows that transplantation of mesenchymal stem cells is insufficient and needs to be combined with inhibition of catabolism. Purpose: Osteoarthritis (OA) is a condition that involves extensive cartilage and bone damage. Adult Mesenchymal Stem Cells (MSCs) are multipotent cells whose primary reservoir is bone marrow. Following situations of extensive tissue damage, MSC are mobilized and migrate to the site of injury along a chemotactic gradient, contributing significantly to local tissue repair. Until now, various molecules that modulate chemotactic migration of MSCs have been reported. Platelet-derived growth factor (PDGF), a polypeptide formed by two amino acid chains of two related genes, is a powerful chemotactic factor for mesenchymal cells, including osteoblasts from human and rat tissue. The products of the PDGF A and PDGF B genes can form homodimers or heterodimers, so PDGF could act in three isoforms: PDGF-AA, PDGF-BB, or PDGF-AB. PDGF-BB may be more specific for MSCs and their recruitment from long distances, being chemoattractive for the progenitor cells even at the lowest concentrations. The aim of this study was to assess the chemotactic effects of PDGF-BB on primary human MSCs from patients with OA and to compare the results with those of primary human MSCs from healthy controls.
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Osteoarthritis and Cartilage Vol. 16 Supplement 4 Methods: Confluent MSCs from 6 OA patients and 6 controls were trypsinized, counted, and then washed once by centrifugation. Chemotaxis responses were measured using 24-well cell-culture chambers (Transwell ® Permeable Supports; Corning, NY), with inserts of 6.5-mmdiameter and 8-mm pore polycarbonate membranes. Cells (2×10 4 ) in 0.1 ml DMEM were seeded on the upper chambers and incubated for 2 hour at 37 ºC in 5% CO 2 to allow cell attachment and spreading. After the cells had attached to the Transwell ® membranes, 0.6 ml culture medium containing 1 ng/ml rhPDGF-BB (R&D Systems Inc.) was added to the lower compartment. Following 4 h of incubation at the same temperature, the cells on the upper surface of the membrane were removed with a cotton swab, and the remaining migrated cells on the lower side of the filter were fixed with 4% formaldehyde and stained with crystal violet. Control wells with only DMEM in the bottom well were included in each experiment. All measurements were from at least six independent experiments performed in triplicate. The number of migrated cells in the control and stimulated wells was counted for 10 random fields per well at 100× magnification. Results were expressed as a chemotactic index (CI). This index was determined as the average number of migrated cells in stimulated wells divided by the average number of migrated cells in control wells. Data were statistically analysed with the Mann-Whitney U test for comparison of the two groups. Results are presented as means±standard deviation. A value of P < 0.05 was considered statistically significant. Results: rhPDGF-BB (1 ng/ml) added to the bottom compartment of the Transwell insert caused a significant increase in migrating MSCs from patients with OA compared to controls (CI: 5.13±1.19 vs. 3.35±0.42, p = 0.043). When identical amounts of rhPDGF-BB were simultaneously added to the both the upper and the lower compartments, the cell migration of MSC remained unchanged. Conclusions: These data could indicate an activation of MSCs from bone marrow in OA in response to permanent signals sent by the bone and cartilage damage characteristic of this disease. Purpose: To design tissue engineered cartilage with improved attachment to a porous calcium polyphosphate (CPP) bone substitute (biphasic construct) by the formation of a zone of calcified cartilage (ZCC) at the cartilage-CPP interface zone. Methods: Cartilage-CPP biphasic implants were formed by seeding chondrocytes isolated from the deep-zone of bovine articular cartilage onto the top surface of porous CPP substrates coated with a thin solgel-formed hydroxyapatite film. The cells were grown in Ham's F12 containing 20% FBS in the absence or presence of b-glycerophosphate supplementation to induce mineralization. After 8 weeks, tissues were harvested and examined histologically, biochemically, by RT-PCR for gene expression and for the shear properties of the interface between cartilage and the substrate using a specifically designed shear test apparatus. Results: Histological sections stained with toluidine blue and von Kossa demonstrated cartilage tissue with a thin ZCC when cultured in mineralization-inducing media. The ZCC was localized in the tissue directly above the substrate, mimicking osteochondral zonal organization. The mineral formed in cartilage in vitro under these conditions has similar composition and crystal size to that present in the ZCC of native cartilage. Conversely, no calcification was observed in cartilage formed in the absence of b-glycerophosphate. Collagen and glycosaminoglycan contents were similar for tissues with and without a calcified zone. Expression levels of cartilage extracellular matrix genes including collagen type II and type X were not affected by the generation of a ZCC. Interestingly, the shear stiffness of the interface was increased by 2-fold in the tissue engineered cartilage with a ZCC compared to cartilage without a ZZC. This was associated with 240% improvement in the peak shear load and in 340% increase in energy to failure measurements. The maximal displacement prior to failure was similar in both tissues. Conclusions: This study demonstrates a significant increase in interfacial shear properties of biphasic cartilage constructs by mimicking the zonal organization of articular cartilage by generating a ZCC at the tissue/bone substitute interface. Generating biphasic cartilage constructs with a calcified cartilage interface will be critical for the clinical success of biphasic constructs used to repair larger joint defects.
THE PRESENCE OF A CALCIFIED INTERFACE
STRENGTHENS TISSUE ENGINEERED CARTILAGE-SUBSTRATE INTERFACIAL SHEAR STRENGTH
THE EFFECT OF LOW-INTENSITY PULSED ULTRASOUND
FOR FORMING OF SCAFFOLD-FREE CARTILAGE TISSUE IN VITRO
K. Uenaka, S. Imai, K. Ando, S. Shioji, Y. Matsusue. Department of Orthopaedic Surgery, Shiga University of Medical Science, Otsu, Shiga, JAPAN Purpose: The aim of this study is to evaluate the effect of low-intensity pulsed ultrasound (LIPUS) for forming of scaffold-free cartilage in vitro culture. Methods: Chondrocytes were collected from articular cartilage of Wistar rats. For acquirement the number of cells, the collected primary chondrocytes (passage 0) were cultured up to subconfluent in 500 cm 2 square dishes. The cells were then condensed to the density at 10 7 cells/cm 2 (passage 1) on synthetic membranes. The LIPUS application group was stimulated by LIPUS for 20 min/day. The mode of the applied ultrasound is a 200 ms burst sine wave of 1.5 MHz repeating at 1 kHz with an intensity of 30 mW/cm 2 . To investigate effect LIPUS stimulation on the matrix-synthesis of the tissues, mRNA expression of type II collagen (col2), aggrecan and type I collagen (col1) was studied using real-time polymerase chain reaction. Synthesis of type II collagen and proteoglycan was also assessed histochemically in 4weeks culture. Results: In our previous study, we presented that high-density culture with P1 chondrocytes more than 10 6 cells/cm 2 could form a cell mass as scaffold-free cartilage tissue under existing cell-cell interactions. In this way, the chondrocytes prepared at 10 7 cells/cm 2 automatically detached from the membranes to form a mass of chondrocytes around the third day of starting P1 culture. After forming the mass, they were moved to simple 6 well dishes for oxygen and nutrition diffusion. The expression of col2 and aggrecan mRNA was significantly higher in the group by stimulation of LIPUS than the group by no stimulation. The resultant scaffold-free cartilage like tissues formed via cell condensation at 10 7 cells/cm 2 grew in thickness until the 7th day of P1 culture. They grew in size until the 14th day of P1 culture. The tissues were stained strongly with safranin O, and there were partially columnar pattern. Immunohistochemical analysis revealed that typeIIcollagen was abundantly deposited in the tissues. Moreover with toluidine blue staining, there was a metachromatic matrix in them. Respectively, LIPUS stimulation group was more strongly stained than the control group. Conclusions: The chondrocytes of P1 cells prepared at 10 7 cells/cm 2 developed into scaffold-free cartilage like tissue under existing cell-cell interactions. As a result of application of LIPUS, we could form scaffoldfree cartilage like tissues which were similar to native cartilage. Purpose: Osteochondral lesions of the talus are frequent occurrences in young active patients. Various surgical options have been proposed over time in order to restore a continuous and adequate cartilaginous layer at the lesion site. Among them, only mosaicplasty and Autologous Chondrocyte Implantation (ACI) were capable, up to now, to restore hyaline cartilage at the lesion site, although major disadvantages of these techniques have been widely described. These considerations leaded in search of new methods for cartilage repair and recently the use of Bone Marrow-Derived Cells (BMDCs) was indicated as a reliable alternative for the treatment of articular cartilage defects. The aim of this study was to verify the ability of an original technique based upon BMDCs to regenerate hyaline articular cartilage, and to compare the clinical and histological results with them obtained after ACI. Methods: From October 2005 to April 2008, 50 patients affected by osteochondral lesions of the talus >1.5 cm 2 underwent a new arthroscopic "One Step" procedure by using bone marrow harvested from the iliac crest, directly concentrated in Operatory Room and seeded on a scaffold with the addition of Platelet-Rich-Fibrin (PRF). Patients evaluation included clinical AOFAS score, X-Rays, MRI preoperatively and at different established follow-up. A series of 46 patients operated by ACI procedure and comparable for age and lesion types was used as control group. At 12 months follow up after "One Step" procedure, an arthroscopic second look and a biopsy of the regenerated cartilage
